In last trading session, INmune Bio Inc (NASDAQ:INMB) saw 0.5 million shares changing hands with its beta currently measuring 1.62. Company’s recent per share price level of $7.27 trading at -$0.5 or -6.44% at ring of the bell on the day assigns it a market valuation of $166.70M. That closing price of INMB’s stock is at a discount of -74.97% from its 52-week high price of $12.72 and is indicating a premium of 40.58% from its 52-week low price of $4.32. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.3 million shares which gives us an average trading volume of 380.19K if we extend that period to 3-months.
INmune Bio Inc (NASDAQ:INMB) trade information
Upright in the red during last session for losing -6.44%, in the last five days INMB remained trading in the red while hitting it’s week-highest on Wednesday, 04/02/25 when the stock touched $7.27 price level, adding 10.91% to its value on the day. INmune Bio Inc’s shares saw a change of 55.67% in year-to-date performance and have moved -3.32% in past 5-day. INmune Bio Inc (NASDAQ:INMB) showed a performance of -9.35% in past 30-days. Number of shares sold short was 5.58 million shares which calculate 22.6 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 22 to the stock, which implies a rise of 66.95% to its current value. Analysts have been projecting 22 as a low price target for the stock while placing it at a high target of 22. It follows that stock’s current price would drop -202.61% in reaching the projected high whereas dropping to the targeted low would mean a loss of -202.61% for stock’s current value.
INmune Bio Inc (INMB) estimates and forecasts
This year revenue growth is estimated to rise 64,757.14% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.07% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 15.01% while estimates for its earnings growth in next 5 years are of 14.10%.
INmune Bio Inc (NASDAQ:INMB)’s Major holders
Insiders are in possession of 27.78% of company’s total shares while institution are holding 27.69 percent of that, with stock having share float percentage of 38.33%. Investors also watch the number of corporate investors in a company very closely, which is 27.69% institutions for INmune Bio Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at INMB for having 0.81 million shares of worth $7.17 million. And as of 2024-06-30, it was holding 4.2103 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 0.63 million shares on 2024-06-30. The number of shares represents firm’s hold over 3.4854 of outstanding shares, having a total worth of $5.54 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 434.27 shares of worth $3.16 million or 1.89% of the total outstanding shares. The later fund manager was in possession of 339.71 shares on Feb 28, 2025 , making its stake of worth around $2.47 million in the company or a holder of 1.48% of company’s stock.
